Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Tirzepatide for diabetes: on track to SURPASS current therapy

A prospective meta-analysis supports the cardiovascular safety of the dual incretin receptor agonist tirzepatide, after promising clinical outcomes in the SURPASS-4 study.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Tirzepatide: a dual GLP-1 and GIP agonist.


  1. McMurray, J. J. V. et al. N. Engl. J. Med. 381, 1995–2008 (2019).

    CAS  Article  Google Scholar 

  2. Anker, S. D. et al. N. Engl. J. Med. 385, 1451–1461 (2021).

    CAS  Article  Google Scholar 

  3. Marso, S. P. et al. N. Engl. J. Med. 375, 1834–1844 (2016).

    CAS  Article  Google Scholar 

  4. Gerstein, H. C. et al. Lancet 394, 121–130 (2019).

    CAS  Article  Google Scholar 

  5. Frías, J. P. et al. N. Engl. J. Med. 385, 503–515 (2021).

    Article  Google Scholar 

  6. Del Prato, S. et al. Lancet (2021).

    Article  PubMed  Google Scholar 

  7. Sattar, N. et al. Nat. Med. (2022).

    Article  PubMed  Google Scholar 

  8. Nauck, M. A. et al. J. Clin. Invest. 91, 301–307 (1993).

    CAS  Article  Google Scholar 

  9. Christensen, M. B., Calanna, S., Holst, J. J., Vilsbøll, T. & Knop, F. K. J. Clin. Endocrinol. Metab. 99, E418–E426 (2014).

    CAS  Article  Google Scholar 

  10. Mentis, N. et al. Diabetes 60, 1270–1276 (2011).

    CAS  Article  Google Scholar 

  11. Nauck, M. A., Quast, D. R., Wefers, J. & Pfeiffer, A. F. H. Diabetes Obes. Metab. (2021).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Christian T. Ruff.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Moura, F.A., Scirica, B.M. & Ruff, C.T. Tirzepatide for diabetes: on track to SURPASS current therapy. Nat Med 28, 450–451 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing